Kura Oncology (KURA) Liabilities and Shareholders Equity (2010 - 2026)

Kura Oncology (KURA) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $652.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 12.26% year-over-year to $652.6 million; the TTM figure through Mar 2026 stood at $2.7 billion (up 9.0% YoY), while the FY2025 annual figure was $738.4 million, down 2.87% from the prior year.
• Liabilities and Shareholders Equity eased to $652.6 million in Q1 2026 per KURA's latest filing, from $738.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $760.2 million in Q4 2024 and bottomed at $426.0 million in Q1 2023.
• Historically, Liabilities and Shareholders Equity has averaged $558.4 million across 5 years, with a median of $498.6 million in 2022.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity declined 20.16% — and 2024, when it soared 69.32%.
• Kura Oncology's Liabilities and Shareholders Equity stood at $456.3 million in 2022, then declined by 1.62% to $448.9 million in 2023, then soared by 69.32% to $760.2 million in 2024, then fell by 2.87% to $738.4 million in 2025, then declined by 11.62% to $652.6 million in 2026.
• Business Quant data shows KURA's Liabilities and Shareholders Equity at $652.6 million in Q1 2026, $738.4 million in Q4 2025, and $649.4 million in Q3 2025.